These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22338476)

  • 1. [Association of TNF-alpha polymorphism (-308 A/G) with high activity of rheumatoid arthritis and therapy response to Etanercept].
    Stojanović S; Jevtović-Stoimenov T; Stanković A; Pavlović D; Neković J; Stamenković B; Dimić A; Marinković M
    Srp Arh Celok Lek; 2011; 139(11-12):784-9. PubMed ID: 22338476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
    Guis S; Balandraud N; Bouvenot J; Auger I; Toussirot E; Wendling D; Mattei JP; Nogueira L; Mugnier B; Legeron P; Landt O; Serre G; Roudier J; Roudier C
    Arthritis Rheum; 2007 Dec; 57(8):1426-30. PubMed ID: 18050183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.
    Jančić I; Arsenović-Ranin N; Sefik-Bukilica M; Zivojinović S; Damjanov N; Spasovski V; Srzentić S; Stanković B; Pavlović S
    Rheumatol Int; 2013 Jun; 33(6):1481-6. PubMed ID: 23233117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
    Padyukov L; Lampa J; Heimbürger M; Ernestam S; Cederholm T; Lundkvist I; Andersson P; Hermansson Y; Harju A; Klareskog L; Bratt J
    Ann Rheum Dis; 2003 Jun; 62(6):526-9. PubMed ID: 12759288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
    Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
    Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.
    Kang CP; Lee KW; Yoo DH; Kang C; Bae SC
    Rheumatology (Oxford); 2005 Apr; 44(4):547-52. PubMed ID: 15695296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab].
    Sanmartí R; Gómez-Puerta JA; Rodríguez-Cros JR; Albaladejo C; Muñoz-Gómez J; Cañete JD
    Med Clin (Barc); 2004 Mar; 122(9):321-4. PubMed ID: 15033049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E; Freundlich B; Schiff M; Li J; Hooper M
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis.
    Suzuki Y; Inoue K; Chiba J; Inoue Y; Kanbe K
    Int J Rheum Dis; 2009 Apr; 12(1):7-13. PubMed ID: 20374310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
    Koyama Y; Shiraishi H; Ohta T; Uchino A
    Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial.
    Kameda H; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Takeuchi T;
    Mod Rheumatol; 2010 Dec; 20(6):531-8. PubMed ID: 20574649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
    Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
    Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.